



Cognitive impairments by alcohol and sleep deprivation indicate trait characteristics and a potential role for adenosine A₁ receptors

Eva-Maria Elmenhorst^{a,b,1,2}, David Elmenhorst^{c,d,1}, Sibylle Benderoth^a, Tina Kroll^c, Andreas Bauer^{c,e,3}, and Daniel Aeschbach^{a,f,g,3}

^aDepartment of Sleep and Human Factors Research, Institute of Aerospace Medicine, German Aerospace Center (DLR), 51170 Cologne, Germany; ^bInstitute for Occupational, Social and Environmental Medicine, Medical Faculty, Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen University, 52074 Aachen, Germany; ^cInstitute of Neuroscience and Medicine (INM-2), Forschungszentrum Jülich, 52425 Jülich, Germany; ^dDepartment of Psychiatry and Psychotherapy, Rheinische Friedrich Wilhelms University Bonn, 53105 Bonn, Germany; ^eNeurological Department, Medical Faculty, Heinrich Heine University, 40225 Düsseldorf, Germany; ^fDivision of Sleep and Circadian Disorders, Brigham and Women's Hospital, Boston, MA 02115; and ^gDivision of Sleep Medicine, Harvard Medical School, Boston, MA 02115

Edited by Joanna S. Fowler, Brookhaven National Laboratory, Upton, NY, and approved June 18, 2018 (received for review March 23, 2018)

Trait-like differences in cognitive performance after sleep loss put some individuals more at risk than others, the basis of such disparities remaining largely unknown. Similarly, interindividual differences in impairment in response to alcohol intake have been observed. We tested whether performance impairments due to either acute or chronic sleep loss can be predicted by an individual's vulnerability to acute alcohol intake. Also, we used positron emission tomography (PET) to test whether acute alcohol infusion results in an up-regulation of cerebral A₁ adenosine receptors (A₁ARs), similar to the changes previously observed following sleep deprivation. Sustained attention in the psychomotor vigilance task (PVT) was tested in 49 healthy volunteers (26 ± 5 SD years; 15 females) (i) under baseline conditions: (ii) after ethanol intake, and after either (iii) total sleep deprivation (TSD; 35 hours awake; n = 35) or (iv) partial sleep deprivation (PSD; four nights with 5 hours scheduled sleep; n = 14). Ethanol- versus placebo-induced changes in cerebral A₁AR availability were measured in 10 healthy male volunteers (31 ± 9 years) with [¹⁸F]8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine (CPFPX) PET. Highly significant correlations between the performance impairments induced by ethanol and sleep deprivation were found for various PVT parameters, including mean speed (TSD, r = 0.62; PSD, r = 0.84). A₁AR availability increased up to 26% in several brain regions with ethanol infusion. Our studies revealed individual trait characteristics for being either vulnerable or resilient to both alcohol and to sleep deprivation. Both interventions induce gradual increases in cerebral A₁AR availability, pointing to a potential common molecular response mechanism.

ethanol | sleep deprivation | adenosine receptor | trait vulnerabilities | human

Fatigue due to sleep loss and extended time awake is a major cause of accidents and incidents in the modern 24-h society (1–6). Surveys on sleep habits suggest that ~40% of the German population (7) and ~30% of the US population (2, 8) sleep less than the recommended 7-h minimum sleep duration (9). Chronic sleep restriction is associated with increased sleepiness and cognitive performance impairment (10–13). The extent of impairment varies greatly among individuals, putting some more at risk than others (14, 15), whereas the physiological basis of this variation remains largely unknown. In contrast, performance varies relatively little across repeated exposures within an individual, indicating trait-like behavior (16) and a substantial genetic influence (17). For a comprehensive review on the interindividual neurobehavioral variation in the response to sleep deprivation and its involvement of adenosinergic, dopaminergic, and cholinergic pathways, see Tkachenko and Dinges (18). Similarly, trait-like differences exist in alcohol sensitivity and the vulnerability to performance impairment

after alcohol intake (19). Ethanol is a psychoactive drug with depressant effects on the central nervous system. For example, alcohol facilitates sleep onset and increases deep sleep in the first half of the sleep episode, whereas it disrupts sleep in the second half of the sleep episode (20, 21). It affects multiple neuroreceptor systems in the brain: It is a positive allosteric modulator at GABA receptors, agonist at the alpha 7 nicotinic acetylcholine and serotonin 3 receptors, antagonist at the NMDA, AMPA, and kainate receptors, and inhibitor of various ion channels. Moreover, ethanol blocks the reuptake of adenosine and increases its formation. Adenosine is a nucleoside that plays a central role in energy transfer, as it is formed by breakdown of ATP, the main energy source of cells. In the brain, adenosine acts as a neuromodulator and cotransmitter that inhibits the impact of excitatory neurotransmitters like glutamate. The physiological effect of adenosine is mediated by four types of receptors, of which the A₁ subtype is most widespread in the human brain. The brain's adenosine system has emerged as a potential candidate mediating both the sleep-inducing effects of alcohol as well as the increase in sleep propensity and sleepiness after sleep loss. The impairment of

Significance

Modern work environments favor working around the clock, at the cost of insufficient sleep and increased risk for fatigue-related human error. Performance impairments caused by sleep loss show great variability among individuals and resemble the effects of ethanol intoxication. We found that there are individual trait characteristics that make individuals either vulnerable or resilient to both alcohol and to sleep deprivation. We also provide evidence by molecular brain imaging that ethanol induces an up-regulation of cerebral A₁ adenosine receptors, reminiscent of the effects of sleep deprivation. Targeting the brain's adenosine system might help to identify countermeasures for fatigue- and alcohol-related human error.

Author contributions: E.-M.E., D.E., A.B., and D.A. designed research; E.-M.E., D.E., S.B., and T.K. performed research; E.-M.E. and D.E. contributed new reagents/analytic tools; E.-M.E. and D.E. analyzed data; and E.-M.E., D.E., A.B., and D.A. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

Published under the PNAS license.

¹E.-M.E. and D.E. contributed equally to this work.

²To whom correspondence should be addressed. Email: eva-maria.elmenhorst@dlr.de.

³A.B. and D.A. contributed equally to this work.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803770115/-DCSupplemental.

Published online July 16, 2018.

alertness and motor/cognitive performance by alcohol (22) is attributed to the inhibitory effects of increased adenosine concentration and to an increase of inhibitory A₁ adenosine receptor (A₁AR) availability (23–25). The increase in extracellular adenosine has been reported to inhibit wake-promoting cholinergic neurons in the basal forebrain, since blocking the A₁AR as well as lesioning of cholinergic neurons in the basal forebrain resulted in a reduction of the sedative effect of ethanol (26). Ethanol was found to increase extracellular adenosine levels up to fourfold in cell culture and in vivo microdialysis experiments by stimulating its production and by uptake inhibition (27). Agonists at the A₁AR such as cyclohexyladenosine are known to accentuate the effects of ethanol, whereas A₁AR antagonists like caffeine and theophylline attenuate them. Sleep deprivation increases A₁AR availability in the human brain as a function of elapsed time awake (28), thereby impairing brain functioning.

We hypothesized that (i) the individual performance-degrading effects of sleep loss and alcohol correlate, that is, that the response to alcohol predicts individual vulnerability to sleep loss, and that (ii) ethanol induces a global increase in A₁AR availability in the human brain resembling the effects of sleep loss.

Three studies were conducted to test these hypotheses. First, 47 participants were exposed to alcohol and 38 h of wakefulness on separate days to compare the impairment of sustained attention on an individual basis. Second, individual impairment was compared in 16 participants who were exposed to alcohol and 4 d of partial sleep deprivation (5-h time in bed) on separate days. Third, cerebral A₁AR availability of 10 participants was measured in vivo using positron emission tomography (PET) comparing the impact of ethanol versus placebo infusion.

Results

Alcohol intake, total sleep deprivation, and 4 d of sleep restriction each resulted in impairment of sustained attention, measured as the deviation from baseline in a psychomotor vigilance task (PVT) (Fig. 1). Individuals who showed good performance after alcohol intake proved to be more resistant to the effects of acute and chronic sleep loss, whereas individuals who showed large impairments after alcohol were more vulnerable to the two types of sleep deprivation (Fig. 1 A and B). A median split was performed based on individuals' performance under the influence of alcohol. The resulting two groups differed significantly in mean speed during total sleep deprivation (TSD) and partial sleep deprivation (PSD) (Fig. 2). While the resilient group recovered from sleep loss after one night of sleep, recovery remained incomplete in the vulnerable group.

Highly significant Spearman correlations (Fig. 1 C and D and Table 1) between performance impairments after alcohol intake and acute or chronic sleep deprivation were found for several PVT measures. In contrast, the impairment in the examined performance parameters under alcohol or sleep deprivation did not depend on an individual's absolute performance at baseline (i.e., no significant correlation except for the 10% slowest reaction times after sleep deprivation; $P = 0.048$). Moreover, the small differences in blood alcohol concentration (BAC) levels between subjects did not predict performance impairment ($r < 0.36$, $P > 0.2$).

Using quantitative [¹⁸F]8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine (CPFPX) PET, ethanol infusion rapidly increased A₁AR availability in various brain regions, while placebo infusion had no such effect (Figs. 3 and 4). Comparison between the posttreatment interval (i.e., 110 to 140 min after tracer infusion) and the baseline interval (50 to 90 min) revealed for the ethanol group a relative increase in A₁AR availability ranging




Fig. 1. Comparison of psychomotor vigilance task performance impairment by ethanol, total sleep deprivation (A and C), and partial sleep deprivation (B and D). (A and B) Individual impairment in 10% slowest reaction times (RTs; means; difference from baseline) after alcohol (diamonds) and sleep deprivation (circles), ordered according to impairment after alcohol. Intraclass correlation coefficients (ICCs; two-way mixed effects model, absolute agreement) indicate moderate agreement. Note that the degree of impairment did not vary due to differences in blood alcohol concentration [color-coded diamonds ranging from orange (low concentration) to black (high concentration)]. (C and D) Significant Spearman correlations between the impairment (difference from baseline) in mean speed under alcohol and after sleep deprivation (see also Table 1).




Fig. 2. Time course of mean speed in the psychomotor vigilance task during (A) total sleep deprivation (TSD), after (B) repeated partial sleep deprivation (PSD), and after recovery (REC) sleep. Based on performance impairment under alcohol, the subjects were divided into two subgroups (median split). Gray vertical bars represent sleep periods. Error bars indicate SEM. * $P < 0.05$ for differences between subgroups (unpaired t tests).

from $20 \pm 5\%$ SEM (amygdala) to $26 \pm 5\%$ (cuneus), depending on the brain region. In comparison, under identical control conditions (placebo group), there were no significant differences in any brain region (variation of $3 \pm 3\%$ across examined regions). Details are displayed in Table 2. The increase in A_1AR availability showed large interindividual differences that were not correlated with BAC (Fig. 4B).

The Biphasic Alcohol Effects Scale (BAES), which is a measure of alcohol's stimulating and sedating effects, showed in the sedating subscale a significant correlation with the treatment-dependent relative changes in the A_1AR in several brain regions (SI Appendix, Table S1). Exemplarily, the striatum (left and right; $r = -0.99$, $P = 0.0001$) is depicted in Fig. 4C. Importantly, the BAES did not show a correlation with BAC ($r = -0.05$, $P = 0.91$).

Discussion

The present study shows that cognitive performance impairments due to ethanol intake and sleep loss correlate strongly across individuals, indicating the presence of an underlying trait vulnerability. The present study also reveals that acute ethanol administration is accompanied by a rapid increase in A_1AR availability in the human brain and that the subjective sedating effects as assessed by the BAES correlate strongly with cerebral A_1AR availability. Given the previously observed up-regulation of A_1AR availability with extended time awake (28, 29), the cerebral adenosine system might therefore represent a common pathway for both ethanol and sleep deprivation effects on performance. Behavioral studies have established a link between both stressors, providing evidence for additive or even synergistic detrimental effects on cognitive performance (30–33).

Table 1. PVT performance impairment after total and partial sleep deprivation and alcohol administration

PVT parameter	TSD	Ethanol	Spearman	PSD	Ethanol	Spearman
	Mean Δ (SEM)	Mean Δ (SEM)	r value P value	Mean Δ (SEM)	Mean Δ (SEM)	r value P value
Median RT, ms	36.92 (10.03)	31.96 (4.91)	0.567 0.0004	4.10 (4.73)	23.51 (8.10)	0.862 <0.0001
Mean speed, 1/s	-0.64 (0.11)	-0.47 (0.07)	0.620 <0.0001	-0.07 (0.10)	-0.41 (0.13)	0.842 0.0002
10th percentile speed, 1/s	-1.25 (0.23)	-0.64 (0.10)	0.603 0.0001	-0.16 (0.14)	-0.53 (0.16)	0.886 <0.0001
90th percentile speed, 1/s	-0.29 (0.06)	-0.32 (0.06)	0.614 <0.0001	0.05 (0.08)	-0.27 (0.10)	0.833 0.0002
Lapses, no.	5.14 (1.29)	1.60 (0.48)	0.508 0.0018	1.43 (0.72)	2.43 (1.15)	0.281 0.5410
Mean RT, ms	29.99 (4.20)	33.08 (4.76)	0.659 <0.0001	4.89 (5.19)	24.00 (8.22)	0.846 0.0001
SD of RT, ms	19.70 (2.59)	14.99 (2.08)	0.742 <0.0001	6.14 (2.78)	10.12 (3.28)	0.574 0.0320
Mean 10% slowest RT, ms	74.73 (9.78)	65.58 (8.50)	0.662 <0.0001	17.00 (11.29)	42.49 (13.76)	0.666 0.0093
Mean 10% fastest RT, ms	8.47 (2.08)	12.97 (2.80)	0.462 0.0052	-1.80 (3.53)	9.72 (4.16)	0.846 0.0001

PSD, after four nights with time in bed restricted to 5 h; RT, reaction time; TSD, 35 h awake. Median RT and parameters of speed include all RTs. Lapses are RTs ≥ 500 ms; other PVT parameters are based on RT excluding lapses. Mean Δ is the difference between experimental condition (TSD, PSD, ethanol) and baseline at respective daytimes; 10th percentile refers to difference in slow response speed, and 90th percentile to difference in fast response speed. Significant correlations are bold.




Fig. 3. Effects of ethanol infusion on cerebral A_1 adenosine receptor availability. Spatially normalized averaged images of anatomy (A; MRI) and adenosine receptor availability (B and C; PET distribution volume) of the ethanol-receiving subjects ($n = 7$) during the baseline interval (average of 50 to 80 min after the start of radioligand infusion) and during the posttreatment interval (110 to 140 min) are shown. (Left) Axial views. (Middle) Sagittal views. (Right) Coronal views.

The large interindividual variation in the susceptibility of cognitive performance to acute and chronic sleep deprivation that we found here substantiates previous reports (15, 34) and is consistent with a genetic contribution (e.g., refs. 35 and 36). Large interindividual variations have also been reported for the wakefulness- and performance-promoting effects of caffeine (37), which is known to act via adenosine receptor antagonism (38). Individual differences in caffeine sensitivity have been linked to genetic variations in the adenosine system (39, 40). In a recent study using PET, we found that the degree of an individual's performance impairment after extended time awake was related to cerebral A_1 AR availability (29). Taken together, the adenosine system appears to be subject to individual variations that in turn contribute to the differences in the vulnerability to sleep loss.

The increase in A_1 AR availability in humans after ethanol exposure confirms previous reports of *in vitro* and *in vivo* experiments in rodents. Autoradiography experiments in rats showed that 1.5 g/kg ethanol led to a 40% increase in A_1 AR availability after only 15 min (23). A 35 to 55% increase in distribution volume was measured 20 min after application of ethanol along with an adenosine kinase inhibitor (25). Recent results from mice suggest that sleep deprivation attenuates the sensitivity to alcohol via reducing extracellular accumulation of adenosine in a long-lasting manner (41). The magnitude of the 35% increase in cerebral A_1 AR availability after alcohol infusion in the present study is comparable to a respective decrease observed after four cups of espresso (42).

Caffeine has been reported to be an effective countermeasure against performance impairment in the PVT during sleep deprivation, sleep inertia (43–45), as well as circadian misalignment (43–45). Although numerous studies have investigated caffeine as an antidote for alcohol-related performance decrements, outcomes remain equivocal (43–47). Moreover, there are differences in their neurochemical action, as the antagonist caffeine blocks receptor binding whereas ethanol rapidly increases A_1 AR availability through a mechanism that has not been clarified so far. It is possible that alcohol slows down the turnover of cell-surface receptors and increases receptor trafficking to the cell surface.

Mechanisms could be an enhancement of an intracellular receptor pool that involves receptor assembly and maturation or sensitization (at least in the basal ganglia) by A_1 adenosine- D_1 dopamine receptor heteromeric interaction (48, 49). Nonetheless, the present behavioral and PET studies indicate that alcohol and caffeine may represent at least in part antagonistic drugs, as they appear to interact with a common underlying pathway.

In conclusion, these findings support the framework that there are individual trait characteristics for being either vulnerable or resilient to both alcohol and to sleep deprivation. Based on previous studies on the effects of extended wakefulness (29) and the present findings on ethanol-induced changes in cerebral A_1 AR availability, we provide evidence that both alcohol and sleep deprivation effects are mediated—at least partly—via the adenosine system of the brain. Important related research questions that need to be addressed to corroborate our conclusion are (i) whether individual changes in A_1 AR availability after sleep deprivation correlate with those under ethanol influence, (ii) whether chronic sleep restriction induces alterations of A_1 AR availability in the human brain, and (iii) whether chronic sleep restriction modulates the effect of ethanol on neurobehavioral performance. Targeting the adenosine system might therefore help identify new countermeasures against compromised performance induced by both sleep deprivation and alcohol. Possible countermeasures could include individualized fatigue management systems and training. Furthermore, assessing sensitivity to alcohol might be cautiously used as a means to identify/protect individuals who are at




Fig. 4. Effects of ethanol infusion on cerebral A_1 adenosine receptor availability. (A) Time course of the normalized (to the baseline interval) distribution volume in the frontal cortex of two representative subjects during the steady-state phase of radioligand delivery. Thirty-minute ethanol infusion (0.53 g/kg; black diamonds) or placebo infusion (shaded circles for reference) started at 80 min after the start of the PET experiment during the steady-state phase and continued for 30 min (33 mL/min infusion rate). (B) No correlation between changes in A_1 AR binding and ethanol dose. (C) Significant correlation between changes in A_1 AR binding and changes in ethanol-induced sedating symptoms (Biphasic Alcohol Effects Scale).

Table 2. Relative regional changes of cerebral A₁AR availability after ethanol or placebo administration

Brain region	Relative increase in A ₁ AR availability, %			
	Ethanol group		Control group	
	Mean relative Δ (SEM)	P value	Mean relative Δ (SEM)	P value
Supplementary motor area	24 (5)	0.001	6 (2)	0.047
Frontal inferior	23 (5)	0.001	3 (2)	0.269
Insula	23 (5)	0.002	0 (3)	0.905
Cingulum anterior	25 (5)	0.001	2 (2)	0.434
Hippocampus	20 (4)	0.002	5 (4)	0.287
Amygdala	20 (5)	0.002	5 (6)	0.431
Cuneus	26 (5)	0.001	8 (3)	0.063
Occipital	23 (5)	0.002	3 (2)	0.124
Postcentral	24 (5)	0.001	3 (2)	0.288
Striatum	19 (5)	0.002	1 (3)	0.775
Pallidum	25 (6)	0.003	1 (3)	0.742
Thalamus	22 (5)	0.003	2 (2)	0.440
Temporal	23 (5)	0.002	3 (2)	0.185
Parietal	22 (5)	0.001	3 (2)	0.261

Significant P values after Bonferroni correction (0.05/14 = 0.0035) are in bold. Mean relative Δ is ((postinfusion – baseline)/baseline).

greatest risk to be impaired by sleep loss, for example in safety-critical environments (e.g., transportation, healthcare, and the military) that include extended duration shifts or night work. Especially in situations of high workload and stress, sleep loss can result from sleep disturbances (50) or from trading sleep for additional work hours; in such situations alcohol consumption is increased (51), and thus insight into putative cumulative effects of sleep loss, stress, and alcohol is highly relevant. A recent model that predicts cognitive performance after sleep loss based on putative changes of adenosine and the A₁AR (52) could be extended to the influence of ethanol on performance and be evaluated accordingly. Finally, our studies are important from a public health education point of view. Reports indicate that young drivers believe that driving drowsy is less of a serious problem than driving under the influence of alcohol (53). Our finding of a shared physiological basis raises awareness for the still underestimated danger of driving while sleep-deprived.

Materials and Methods

Alcohol, Sleep Deprivation, and Performance (Studies 1 and 2).

Participants. The studies were approved by the Ethics Committee of the North Rhine Medical Board. Written informed consent was obtained from all participants. Volunteers' physical and psychological health was confirmed with questionnaires and medical examination. They reported normal sleep-wake rhythmicity and conducted no shift work. From a total of 63 healthy volunteers, datasets of 35 participants in study 1 (mean age ± SD 26 ± 5 y, 20 men/15 women) and 14 participants in study 2 (mean age ± SD 27 ± 4 y, 14 men) were included in the present analysis; 14 participants (12 from study 1, 2 from study 2) were excluded (see below).

Study design. The two studies spanned 12 d and 11 nights and were both carried out in the sleep laboratory of the Institute of Aerospace Medicine (German Aerospace Center). Eight participants at a time underwent the experiments, and they were constantly attended by at least two study staff members.

Study 1. Total sleep deprivation. After an adaptation night and two baseline nights (sleep opportunity: 2300 to 0700 hours), participants underwent three experimental conditions administered in a balanced cross-over design. The experimental conditions were (i) 38-h total sleep deprivation, (ii) one night of partial sleep deprivation (i.e., sleep opportunity restricted to 0000 to 0400 hours), and (iii) alcohol administration at 1600 hours followed by partial sleep deprivation (sleep opportunity: 0000 to 0400 hours). The experimental conditions were followed each by two nights of recovery sleep (all recovery nights 2300 to 0700 hours, except for the first recovery night after total sleep deprivation 2100 to 0700 hours).

Study 2. Partial sleep deprivation. Methodological details of the study have been published elsewhere (13, 54). In brief, after an adaptation night and two baseline nights (sleep opportunity: 2300 to 0700 hours), participants underwent 1 d with hypoxia exposure during daytime cognitive testing, 1 d with alcohol administration at 1030 hours (n = 12) or 1600 hours (n = 2), one recovery day/night followed by four nights with restricted sleep opportunities (0000 to 0500 hours), and two recovery nights (sleep opportunity: 2300 to 0700 hours) in a sequential design.

Alcohol administration. In studies 1 and 2, a drink of vodka whose amount was calculated according to sex, weight, height, and age was consumed within 5 min. Participants' BAC was based on calibrated breath alcohol analyzer (Alcotest; Draeger) results immediately before the cognitive testing session at 1800 or 1200 hours. A BAC of more than 0.06% immediately before the respective cognitive testing session was chosen as minimum for inclusion in the analyses. Data of 14 participants (i.e., 12 in study 1, 2 in study 2) had to be excluded due to physical problems like nausea or vomiting or because they did not reach this threshold due to inability to drink the whole amount of vodka. In study 1, the dataset included 35 participants with a mean BAC of 0.074 ± 0.001% SD (minimum 0.064%, maximum 0.095%, 25% quantile 0.065%, 75% quantile 0.078%). In study 2, the 14 participants included in the present analysis had a mean BAC of 0.076 ± 0.009% SD (minimum 0.060%, maximum 0.094%, 25% quantile 0.069%, 75% quantile 0.080%).

Performance measurements. Sustained attention was measured with a 10-min PVT (16) at 3-h intervals during baseline, experimental, and recovery days. Apart from the cognitive testing session, participants engaged in non-vigorous activities such as reading and watching TV.

Statistics. Impairment of cognitive performance in the experimental conditions was assessed by calculating the difference in the PVT measures (e.g., mean speed, etc.) from the respective values during the first baseline day. Spearman rank correlations were calculated to compare performance impairments due to sleep deprivation/restriction with those due to alcohol intake.

Based on participants' impairment in mean speed after alcohol exposure a median split was performed. Unpaired t tests compared the mean speed of the two groups during baseline, sleep deprivation, sleep restriction, and recovery.

Alcohol PET Study (Study 3).

Participants. The study was approved by the Ethics Committee of the Medical Faculty of the University of Duesseldorf and the German Federal Office for Radiation Protection. The study was performed at the PET laboratory of the Institute of Neuroscience and Medicine (Forschungszentrum Jülich). Written informed consent was obtained from all participants. Physical and psychological health was confirmed by medical examination and questionnaires before 10 healthy male volunteers were assigned to the experimental (n = 7; mean age ± SD 31 ± 9 y) or control group (n = 3; mean age ± SD 31 ± 12 y) (nonrandomized, single-blinded).

PET. Three-dimensional data acquisition took place on an ECAT EXACT HR+ scanner (Siemens-CTI). Scan duration was 140 min with radiotracer injection as bolus followed by a constant infusion with a kbol (amount of bolus equaling an infusion of a certain length) value of 63 min. Realignment, coregistration, segmentation, and normalization of PET data and corresponding MRI (acquired on a 3T Siemens Magnetom Trio with MPRAGE sequence) were done with PMOD (version 3.305; PMOD Group). Repeated arterialized venous blood sampling was scheduled at 2, 5, and 10 min, and every 10 min until 80 min and every 5 min subsequently. The total distribution volume V_T in the equilibrium (between 50 and 140 min) is represented by the formula V_T = TAC/C_p, with TAC being the tissue activity concentration and C_p the plasma activity (28).

More details concerning the PET experiment are provided in *SI Appendix. Alcohol administration/subjective effects.* From minute 80 to 110 of the radiotracer infusion, 40 g of ethanol in 1 L saline or solely 1 L saline solution as placebo was infused. To assess the subjective effects of the infusion, we used a German version of the BAES (55) with a slightly modified instruction that did not imply that alcohol was consumed. Subjects were asked to rate how they felt right before the ethanol infusion and at the end of the PET scan.

Statistics. The alcohol response in the PET regional A₁AR distribution volumes (V_T; mL/mL) was quantified in reference to (i) baseline (pre alcohol infusion) and (ii) postinfusion with a t test for pairwise comparisons with a Bonferroni-corrected significance level. Spearman rank correlation was used to evaluate associations between adenosine receptor availability and (i) BAC and (ii) BAES.

ACKNOWLEDGMENTS. We are deeply grateful for the subjects' dedication to participate in the study and for the help of our colleagues at the German Aerospace Center and the Forschungszentrum Jülich in collecting the data. We thank all our partners for collaboration. The research was supported by funds from the aeronautics program of the German Aerospace Center, Deutsche Akademie für Flug- und Reisemedizin and by funds from the Forschungszentrum Jülich.

1. Lee ML, et al. (2016) High risk of near-crash driving events following night-shift work. *Proc Natl Acad Sci USA* 113:176–181.
2. Liu Y, et al. (2016) Prevalence of healthy sleep duration among adults—United States, 2014. *MMWR Morb Mortal Wkly Rep* 65:137–141.
3. Akerstedt T, Philip P, Capelli A, Kecklund G (2011) Sleep loss and accidents—Work hours, life style, and sleep pathology. *Prog Brain Res* 190:169–188.
4. Caldwell JA, Caldwell JL, Schmidt RM (2008) Alertness management strategies for operational contexts. *Sleep Med Rev* 12:257–273.
5. Barger LK, et al.; Harvard Work Hours, Health, and Safety Group (2005) Extended work shifts and the risk of motor vehicle crashes among interns. *N Engl J Med* 352:125–134.
6. Vejvoda M, et al. (2014) Significance of time awake for predicting pilots' fatigue on short-haul flights: Implications for flight duty time regulations. *J Sleep Res* 23:564–567.
7. Schlack R, Hapke U, Maske U, Busch MA, Cohrs S (2013) Häufigkeit und Verteilung von Schlafproblemen und Insomnie in der deutschen Erwachsenenbevölkerung. Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). *Bundesgesundheitsblatt* 56:740–748.
8. Krueger PM, Friedman EM (2009) Sleep duration in the United States: A cross-sectional population-based study. *Am J Epidemiol* 169:1052–1063.
9. Watson NF, et al. (2015) Recommended amount of sleep for a healthy adult: A joint consensus statement of the American Academy of Sleep Medicine and Sleep Research Society. *Sleep* 38:843–844.
10. Cohen DA, et al. (2010) Uncovering residual effects of chronic sleep loss on human performance. *Sci Transl Med* 2:14ra3.
11. Kim Y, et al. (2012) Decoupling of sleepiness from sleep time and intensity during chronic sleep restriction: Evidence for a role of the adenosine system. *Sleep* 35:861–869.
12. Belenky G, et al. (2003) Patterns of performance degradation and restoration during sleep restriction and subsequent recovery: A sleep dose-response study. *J Sleep Res* 12:1–12.
13. Elmenhorst D, et al. (2009) Performance impairment during four days partial sleep deprivation compared with the acute effects of alcohol and hypoxia. *Sleep Med* 10:189–197.
14. Van Dongen HP (2004) Comparison of mathematical model predictions to experimental data of fatigue and performance. *Aviat Space Environ Med* 75(Suppl 3):A15–A36.
15. Van Dongen HP, Belenky G (2009) Individual differences in vulnerability to sleep loss in the work environment. *Ind Health* 47:518–526.
16. Van Dongen HP, Baynard MD, Maislin G, Dinges DF (2004) Systematic interindividual differences in neurobehavioral impairment from sleep loss: Evidence of trait-like differential vulnerability. *Sleep* 27:423–433.
17. Kuna ST, et al. (2012) Heritability of performance deficit accumulation during acute sleep deprivation in twins. *Sleep* 35:1223–1233.
18. Tkachenko O, Dinges DF (2018) Interindividual variability in neurobehavioral response to sleep loss: A comprehensive review. *Neurosci Biobehav Rev* 89:29–48.
19. Bartholow BD, et al. (2003) Effects of alcohol consumption and alcohol susceptibility on cognition: A psychophysiological examination. *Biol Psychol* 64:167–190.
20. Ebrahim IO, Shapiro CM, Williams AJ, Fenwick PB (2013) Alcohol and sleep I: Effects on normal sleep. *Alcohol Clin Exp Res* 37:539–549.
21. Dijk DJ, Brunner DP, Aeschbach D, Tobler I, Borbély AA (1992) The effects of ethanol on human sleep EEG power spectra differ from those of benzodiazepine receptor agonists. *Neuropsychopharmacology* 7:225–232.
22. Dawson D, Reid K (1997) Fatigue, alcohol and performance impairment. *Nature* 388:235.
23. Clark M, Dar MS (1991) In vitro autoradiographic evidence for adenosine modulation of ethanol-induced motor disturbances in rats. *Alcohol Alcohol Suppl* 1:203–206.
24. Jarvis MF, Becker HC (1998) Single and repeated episodes of ethanol withdrawal increase adenosine A1, but not A2A, receptor density in mouse brain. *Brain Res* 786:80–88.
25. Paul S, et al. (2011) Small-animal PET study of adenosine A(1) receptors in rat brain: Blocking receptors and raising extracellular adenosine. *J Nucl Med* 52:1293–1300.
26. Thakkar MM, Sharma R, Sahota P (2015) Alcohol disrupts sleep homeostasis. *Alcohol* 49:299–310.
27. Sharma R, Engemann SC, Sahota P, Thakkar MM (2010) Effects of ethanol on extracellular levels of adenosine in the basal forebrain: An in vivo microdialysis study in freely behaving rats. *Alcohol Clin Exp Res* 34:813–818.
28. Elmenhorst D, et al. (2007) Sleep deprivation increases A1 adenosine receptor binding in the human brain: A positron emission tomography study. *J Neurosci* 27:2410–2415.
29. Elmenhorst D, et al. (2017) Recovery sleep after extended wakefulness restores elevated A1 adenosine receptor availability in the human brain. *Proc Natl Acad Sci USA* 114:4243–4248.
30. Krull KR, Smith LT, Kalbfleisch LD, Parsons OA (1992) The influence of alcohol and sleep deprivation on stimulus evaluation. *Alcohol* 9:445–450.
31. Arnedt JT, Wilde GJS, Munt PW, MacLean AW (2000) Simulated driving performance following prolonged wakefulness and alcohol consumption: Separate and combined contributions to impairment. *J Sleep Res* 9:233–241.
32. Banks S, Catchside P, Lack L, Grunstein RR, McEvoy RD (2004) Low levels of alcohol impair driving simulator performance and reduce perception of crash risk in partially sleep deprived subjects. *Sleep* 27:1063–1067.
33. Lee J, Manousakis J, Fielding J, Anderson C (2015) Alcohol and sleep restriction combined reduces vigilant attention, whereas sleep restriction alone enhances distractibility. *Sleep* 38:765–775.
34. Van Dongen HP, Maislin G, Mullington JM, Dinges DF (2003) The cumulative cost of additional wakefulness: Dose-response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation. *Sleep* 26:117–126.
35. Rupp TL, Wesensten NJ, Newman R, Balkin TJ (2013) PER3 and ADORA2A polymorphisms impact neurobehavioral performance during sleep restriction. *J Sleep Res* 22:160–165.
36. Reichert CF, et al. (2014) Insights into behavioral vulnerability to differential sleep pressure and circadian phase from a functional ADA polymorphism. *J Biol Rhythms* 29:119–130.
37. Rétey JV, et al. (2006) Adenosinergic mechanisms contribute to individual differences in sleep deprivation-induced changes in neurobehavioral function and brain rhythmic activity. *J Neurosci* 26:10472–10479.
38. Urry E, Landolt HP (2015) Adenosine, caffeine, and performance: From cognitive neuroscience of sleep to sleep pharmacogenetics. *Curr Top Behav Neurosci* 25:331–366.
39. Rétey JV, et al. (2007) A genetic variation in the adenosine A2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep. *Clin Pharmacol Ther* 81:692–698.
40. Byrne EM, et al. (2012) A genome-wide association study of caffeine-related sleep disturbance: Confirmation of a role for a common variant in the adenosine receptor. *Sleep* 35:967–975.
41. Clasadonte J, McIver SR, Schmitt LI, Halassa MM, Haydon PG (2014) Chronic sleep restriction disrupts sleep homeostasis and behavioral sensitivity to alcohol by reducing the extracellular accumulation of adenosine. *J Neurosci* 34:1879–1891.
42. Elmenhorst D, Meyer PT, Matusch A, Winz OH, Bauer A (2012) Caffeine occupancy of human cerebral A1 adenosine receptors: In vivo quantification with ¹⁸F-CPPFX and PET. *J Nucl Med* 53:1723–1729.
43. Van Dongen HP, et al. (2001) Caffeine eliminates psychomotor vigilance deficits from sleep inertia. *Sleep* 24:813–819.
44. Wyatt JK, Cajochen C, Ritz-De Cecco A, Czeisler CA, Dijk DJ (2004) Low-dose repeated caffeine administration for circadian-phase-dependent performance degradation during extended wakefulness. *Sleep* 27:374–381.
45. Drake CL, Roehrs T, Turner L, Scofield HM, Roth T (2003) Caffeine reversal of ethanol effects on the multiple sleep latency test, memory, and psychomotor performance. *Neuropsychopharmacology* 28:371–378.
46. Martin FH, Garfield J (2006) Combined effects of alcohol and caffeine on the late components of the event-related potential and on reaction time. *Biol Psychol* 71:63–73.
47. Ferré S (2016) Mechanisms of the psychostimulant effects of caffeine: Implications for substance use disorders. *Psychopharmacology (Berl)* 233:1963–1979.
48. Mundell S, Kelly E (2011) Adenosine receptor desensitization and trafficking. *Biochim Biophys Acta* 1808:1319–1328.
49. Ferré S, O'Brien MC (2011) Alcohol and caffeine: The perfect storm. *J Caffeine Res* 1:153–162.
50. Akerstedt T, Fredlund P, Gillberg M, Jansson B (2002) Work load and work hours in relation to disturbed sleep and fatigue in a large representative sample. *J Psychosom Res* 53:585–588.
51. Buchvold HV, Pallesen S, Øyane NMF, Bjorvatn B (2015) Associations between night work and BMI, alcohol, smoking, caffeine and exercise—A cross-sectional study. *BMC Public Health* 15:1112.
52. Phillips AJK, Klerman EB, Butler JP (2017) Modeling the adenosine system as a modulator of cognitive performance and sleep patterns during sleep restriction and recovery. *PLoS Comput Biol* 13:e1005759.
53. Williams LR, Davies DR, Thiele K, Davidson JR, MacLean AW (2012) Young drivers' perceptions of culpability of sleep-deprived versus drinking drivers. *J Safety Res* 43:115–122.
54. Elmenhorst EM, et al. (2008) Partial sleep deprivation: Impact on the architecture and quality of sleep. *Sleep Med* 9:840–850.
55. Martin CS, Earleywine M, Musty RE, Perrine MW, Swift RM (1993) Development and validation of the Biphasic Alcohol Effects Scale. *Alcohol Clin Exp Res* 17:140–146.